## **Rafaela Holtappels**

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/367308/publications.pdf Version: 2024-02-01



RAFAFLA HOLTADDELS

#	Article	IF	CITATIONS
1	Cytomegalovirus immune evasion sets the functional avidity threshold for protection by CD8 T cells. Medical Microbiology and Immunology, 2023, 212, 153-163.	2.6	10
2	Memory CD8 T Cells Protect against Cytomegalovirus Disease by Formation of Nodular Inflammatory Foci Preventing Intra-Tissue Virus Spread. Viruses, 2022, 14, 1145.	1.5	6
3	Immunodominant Cytomegalovirus Epitopes Suppress Subdominant Epitopes in the Generation of High-Avidity CD8 T Cells. Pathogens, 2021, 10, 956.	1.2	6
4	Consequence of Histoincompatibility beyond GvH-Reaction in Cytomegalovirus Disease Associated with Allogeneic Hematopoietic Cell Transplantation: Change of Paradigm. Viruses, 2021, 13, 1530.	1.5	11
5	Therapeutic Vaccination of Hematopoietic Cell Transplantation Recipients Improves Protective CD8 T-Cell Immunotherapy of Cytomegalovirus Infection. Frontiers in Immunology, 2021, 12, 694588.	2.2	6
6	Revisiting CD8 T-cell â€~Memory Inflation': New Insights with Implications for Cytomegaloviruses as Vaccine Vectors. Vaccines, 2020, 8, 402.	2.1	16
7	Insufficient Antigen Presentation Due to Viral Immune Evasion Explains Lethal Cytomegalovirus Organ Disease After Allogeneic Hematopoietic Cell Transplantation. Frontiers in Cellular and Infection Microbiology, 2020, 10, 157.	1.8	17
8	Coincident airway exposure to low-potency allergen and cytomegalovirus sensitizes for allergic airway disease by viral activation of migratory dendritic cells. PLoS Pathogens, 2019, 15, e1007595.	2.1	19
9	Reconstitution of CD8 T Cells Protective against Cytomegalovirus in a Mouse Model of Hematopoietic Cell Transplantation: Dynamics and Inessentiality of Epitope Immunodominance. Frontiers in Immunology, 2016, 7, 232.	2.2	21
10	Exogenous TNFR2 activation protects from acute GvHD via host T reg cell expansion. Journal of Experimental Medicine, 2016, 213, 1881-1900.	4.2	143
11	Non-cognate bystander cytolysis by clonal epitope-specific CTL lines through CD28–CD80 interaction inhibits antibody production: A potential caveat to CD8 T-cell immunotherapy. Cellular Immunology, 2016, 308, 44-56.	1.4	0
12	Peptide Processing Is Critical for T-Cell Memory Inflation and May Be Optimized to Improve Immune Protection by CMV-Based Vaccine Vectors. PLoS Pathogens, 2016, 12, e1006072.	2.1	55
13	Identification of an atypical CD8 T cell epitope encoded by murine cytomegalovirus ORF-M54 gaining dominance after deletion of the immunodominant antiviral CD8 T cell specificities. Medical Microbiology and Immunology, 2015, 204, 317-326.	2.6	4
14	Mast Cells Expedite Control of Pulmonary Murine Cytomegalovirus Infection by Enhancing the Recruitment of Protective CD8 T Cells to the Lungs. PLoS Pathogens, 2014, 10, e1004100.	2.1	64
15	Noncanonical Expression of a Murine Cytomegalovirus Early Protein CD8 T-Cell Epitope as an Immediate Early Epitope Based on Transcription from an Upstream Gene. Viruses, 2014, 6, 808-831.	1.5	7
16	Spatial distribution and structural arrangement of a murine cytomegalovirus glycoprotein detected by SPDM localization microscopy. Histochemistry and Cell Biology, 2014, 142, 61-67.	0.8	12
17	TCR-Ligand <i>k</i> <sub>off</sub> Rate Correlates with the Protective Capacity of Antigen-Specific CD8 <sup>+</sup> T Cells for Adoptive Transfer. Science Translational Medicine, 2013, 5, 192ra87.	5.8	91
18	Murine cytomegalovirus immune evasion proteins operative in the MHC class I pathway of antigen processing and presentation: state of knowledge, revisions, and questions. Medical Microbiology and Immunology, 2012, 201, 497-512.	2.6	33

RAFAELA HOLTAPPELS

#	Article	IF	CITATIONS
19	Parameters determining the efficacy of adoptive CD8 T-cell therapy of cytomegalovirus infection. Medical Microbiology and Immunology, 2012, 201, 527-539.	2.6	40
20	Immune control in the absence of immunodominant epitopes: implications for immunotherapy of cytomegalovirus infection with antiviral CD8 T cells. Medical Microbiology and Immunology, 2012, 201, 541-550.	2.6	21
21	Antigen presentation under the influence of â€`immune evasion' proteins and its modulation by interferon-gamma: implications for immunotherapy of cytomegalovirus infection with antiviral CD8 T cells. Medical Microbiology and Immunology, 2012, 201, 513-525.	2.6	24
22	In vivo impact of cytomegalovirus evasion of CD8 T-cell immunity: Facts and thoughts based on murine models. Virus Research, 2011, 157, 161-174.	1.1	44
23	Antigen-presenting cells of haematopoietic origin prime cytomegalovirus-specific CD8 T-cells but are not sufficient for driving memory inflation during viral latency. Journal of General Virology, 2011, 92, 1994-2005.	1.3	78
24	CD8 T-Cell Immunotherapy of Cytomegalovirus Disease in the Murine Model. Methods in Microbiology, 2010, , 369-420.	0.4	39
25	Immune Evasion Proteins Enhance Cytomegalovirus Latency in the Lungs. Journal of Virology, 2009, 83, 10293-10298.	1.5	18
26	The Efficacy of Antigen Processing Is Critical for Protection against Cytomegalovirus Disease in the Presence of Viral Immune Evasion Proteins. Journal of Virology, 2009, 83, 9611-9615.	1.5	31
27	Epitope-specific in vivo protection against cytomegalovirus disease by CD8 T cells in the murine model of preemptive immunotherapy. Medical Microbiology and Immunology, 2008, 197, 135-144.	2.6	46
28	CD8 T-cell-based immunotherapy of cytomegalovirus infection: "proof of concept―provided by the murine model. Medical Microbiology and Immunology, 2008, 197, 125-134.	2.6	69
29	Adoptive CD8 T Cell Control of Pathogens Cannot Be Improved by Combining Protective Epitope Specificities. Journal of Infectious Diseases, 2008, 197, 622-629.	1.9	10
30	The Immune Evasion Paradox: Immunoevasins of Murine Cytomegalovirus Enhance Priming of CD8 T Cells by Preventing Negative Feedback Regulation. Journal of Virology, 2008, 82, 11637-11650.	1.5	67
31	Subdominant CD8 T-Cell Epitopes Account for Protection against Cytomegalovirus Independent of Immunodomination. Journal of Virology, 2008, 82, 5781-5796.	1.5	74
32	Cytomegalovirus Encodes a Positive Regulator of Antigen Presentation. Journal of Virology, 2006, 80, 7613-7624.	1.5	69
33	CD8 T Cells Control Cytomegalovirus Latency by Epitope-Specific Sensing of Transcriptional Reactivation. Journal of Virology, 2006, 80, 10436-10456.	1.5	165
34	Highly Protective In Vivo Function of Cytomegalovirus IE1 Epitope-Specific Memory CD8 T Cells Purified by T-Cell Receptor-Based Cell Sorting. Journal of Virology, 2005, 79, 5400-5413.	1.5	102
35	Cytomegalovirus Misleads Its Host by Priming of CD8 T Cells Specific for an Epitope Not Presented in Infected Tissues. Journal of Experimental Medicine, 2004, 199, 131-136.	4.2	108
36	Processing and Presentation of Murine Cytomegalovirus pORF m164 -Derived Peptide in Fibroblasts in the Face of All Viral Immunosubversive Early Gene Functions. Journal of Virology, 2002, 76, 6044-6053.	1.5	55

RAFAELA HOLTAPPELS

#	Article	IF	CITATIONS
37	Two Antigenic Peptides from Genes m123 and m164 of Murine Cytomegalovirus Quantitatively Dominate CD8 T-Cell Memory in the H-2 d Haplotype. Journal of Virology, 2002, 76, 151-164.	1.5	135
38	Animal models: Murine cytomegalovirus. Methods in Microbiology, 2002, , 493-IN11.	0.4	63
39	Early gene m18, a novel player in the immune response to murine cytomegalovirus. Journal of General Virology, 2002, 83, 311-316.	1.3	22
40	Experimental Preemptive Immunotherapy of Murine Cytomegalovirus Disease with CD8 T-Cell Lines Specific for ppM83 and pM84, the Two Homologs of Human Cytomegalovirus Tegument Protein ppUL83 (pp65). Journal of Virology, 2001, 75, 6584-6600.	1.5	46
41	Murine Model of Interstitial Cytomegalovirus Pneumonia in Syngeneic Bone Marrow Transplantation: Persistence of Protective Pulmonary CD8-T-Cell Infiltrates after Clearance of Acute Infection. Journal of Virology, 2000, 74, 7496-7507.	1.5	114
42	The Putative Natural Killer Decoy Early Genem04 (gp34) of Murine Cytomegalovirus Encodes an Antigenic Peptide Recognized by Protective Antiviral CD8 T Cells. Journal of Virology, 2000, 74, 1871-1884.	1.5	63
43	Enrichment of Immediate-Early 1 (m123/pp89) Peptide-Specific CD8 T Cells in a Pulmonary CD62Llo Memory-Effector Cell Pool during Latent Murine Cytomegalovirus Infection of the Lungs. Journal of Virology, 2000, 74, 11495-11503.	1.5	193
44	Identification of a Kd-restricted antigenic peptide encoded by murine cytomegalovirus early gene M84. Journal of General Virology, 2000, 81, 3037-3042.	1.3	26
45	In Vivo Replication of Recombinant Murine Cytomegalovirus Driven by the Paralogous Major Immediate-Early Promoter-Enhancer of Human Cytomegalovirus. Journal of Virology, 1999, 73, 5043-5055.	1.5	44
46	Proliferation and MHC-unrestricted bystander lysis by virus-specific cytotoxic T cells following antigen self-presentation. Medical Microbiology and Immunology, 1998, 187, 17-21.	2.6	3
47	Control of Murine Cytomegalovirus in the Lungs: Relative but Not Absolute Immunodominance of the Immediate-Early 1 Nonapeptide during the Antiviral Cytolytic T-Lymphocyte Response in Pulmonary Infiltrates. Journal of Virology, 1998, 72, 7201-7212.	1.5	100
48	Control of Cytomegalovirus in Bone Marrow Transplantation Chimeras Lacking the Prevailing Antigen-Presenting Molecule in Recipient Tissues Rests Primarily on Recipient-Derived CD8 T Cells. Journal of Virology, 1998, 72, 7733-7744.	1.5	35
49	Preemptive CD8 T-Cell Immunotherapy of Acute Cytomegalovirus Infection Prevents Lethal Disease, Limits the Burden of Latent Viral Genomes, and Reduces the Risk of Virus Recurrence. Journal of Virology, 1998, 72, 1797-1804.	1.5	134